Hard questions.Conservative answers.

No. OPU is presented as a category hypothesis under review. A serious positive outcome still requires both supported Phase 2 solo provenance and strong asset substance; valuation remains a separate diligence question.

It cannot if Phase 1 is included. The one-person claim is explicitly bounded to eligible Phase 2 asset formation. Phase 1 is product and execution context, not solo proof.

It means mapped Phase 2 assets and sub-assets across eight portfolio domains. It does not mean 330 finished products, granted patents, or independently validated systems.

No single maturity label fits the portfolio. Some systems are implemented and internally tested; others are architecture, reference, security research, protocol research or foundational research. The correct question is asset-by-asset maturity.

Do not believe it on narrative. Reconstruct it from timestamps, version history, AI interaction records, tool/account records, contributor records, artifact trails and controlled provenance material.

Not by itself. The boundary concerns material human formation contribution. AI systems and tools are part of the operating model; hidden human contributors materially forming eligible assets would change eligibility.

A clean formation boundary makes provenance testable. That choice can strengthen the provenance experiment, but it does not validate the quality or value of the resulting assets.

Because public review, IP protection, security discipline and responsible disclosure are different requirements. Restricted material is not automatically absent; it is also not independently validated until reviewed under appropriate access.

Because OPU is not a public self-valuation exercise. The site can map strategic substance and review-worthiness; market value requires independent commercial and valuation work.

External signals can show visibility, selection or curiosity. They do not prove solo provenance, technical novelty, IP validity, product readiness or valuation.

Material hidden human formation contribution, unreconstructable provenance, or evidence that contradicts the bounded solo claim can defeat Axis A. Weak/trivial/copied/unsupported asset substance can defeat Axis B.

That is a portfolio-level question. The correct review is to inspect the cross-phase architecture and then test representative assets independently; coherence does not substitute for asset validity.

Operational convergence is a Phase 3 direction. Earlier phases provide product roots, technical assets and research inputs; they should not be retroactively described as a completed Zoyan deployment.

No, provided the claim remains bounded. Later professional review, team formation and commercialization do not retroactively rewrite who materially formed eligible Phase 2 artifacts.

No. Its job is review calibration: classify structural refutation, evidence gaps, phase confusion, disclosure boundaries, documentation hygiene and reviewer-access limits before turning an objection into a verdict.